Uncategorized

Our later well-being and health are heavily impacted by the social conditions in which we are reared.
According to a new study, these events have a major influence on our health risks as adults. The vast majority of Americans (67%) report having experienced at least one traumatic event as a youngster. Obesity and chronic pain are affected physically, but post-traumatic stress disorder (PTSD), bipolar disorder, drug abuse, and depression have the most association with physical disorders. The study was led by researchers from DRI and the University of Nevada, Reno, and was published on October 6 in the journal Frontiers in Psychiatry.

More than 16,000 Reno residents volunteered for the study as part of the Healthy Nevada Project, one of the most publicised genetic studies in the country led by Renown Health. Participants were asked about their social surroundings before the age of 18, including emotional, physical, or sexual maltreatment, neglect, and substance misuse in the home. The researchers used this data in conjunction with anonymised medical records to expand on previous studies into how childhood trauma affects health outcomes.
“The study gives insight into how socioeconomic determinants of health may impact adult health conditions,” said one of the study’s lead authors, Robert Read, M.S., a researcher at DRI’s Center for Genomic Medicine.

Although the study is based on Nevada, which has a high prevalence of individuals with mental illness and limited access to care, the researchers say it gives a glimpse into deeply established public health issues across the country.
“Beating the frequency of childhood traumas is a complicated task,” said Karen Schlauch, Ph.D., a DRI bioinformatics researcher and one of the study’s primary authors. “Personal experiences of neglect and abuse are more difficult to resolve, but many of the underlying factors, like as food insecurity and poverty, may be addressed at the community level.”

Beyond better understanding how early social circumstances impact our health, Schlauch says the next study focus will be on how childhood traumas may be connected to specific qualities like impulsivity, which is prevalent in Nevada’s gaming populations.
“In order to address the devastating effects of early-life adversity on local population health and inequities, we must focus on the dominant social and behavioural mechanisms affecting Nevadans,” said Stephanie Koning, Ph.D., an assistant professor at the University of Nevada, Reno’s School of Public Health and study co-author. “We are collaborating with community-based groups to promote evidence-based solutions at the individual, community, and state levels, in addition to how population needs drive our research.”

The study team is investigating ways to use the Healthy Nevada Project database to support community-based treatments as they broaden their examination of the health effects of early-life trauma. They’ve collaborated with community institutional partners, such as the Stacie Mathewson Behavioral Health & Addiction Institute and Northern Nevada HOPES, to conduct research and advocate for healthy early social contexts and well-being throughout an individual’s life.

Major cultural and political events, according to study, can have a considerable influence on psychological health, as well as sleep and emotional well-being. While popular belief says that highly anticipated events, such as elections, can generate stress and disturb well-being.
Researchers at Beth Israel Deaconess Medical Center (BIDMC) and colleagues have now demonstrated how large geopolitical events may have worldwide effects on sleep, which are related with considerable swings in the public’s collective mood, well-being, and alcohol use. The findings, published in the journal Sleep Health of the National Sleep Foundation, demonstrate that polarising political events had a detrimental impact on a wide range of characteristics associated to public mood.

“Given the political turmoil of the previous several years, it is doubtful that these findings would come as a surprise to many,” said corresponding author Tony Cunningham, PhD, director of BIDMC’s Center for Sleep and Cognition. “Our findings are likely to reflect many of our personal experiences in the aftermath of extremely stressful situations, and we saw this as an opportunity to empirically test these ideas.”

The team surveyed 437 participants in the United States and 106 international participants daily between October 1-13, 2020 (before the election) and October 30-November 12, 2020 (after the election) as part of a larger study investigating the sleep and psychological consequences of the COVID-19 pandemic (days surrounding the November 3 U.S. election). Participants reported on their sleep length and quality, alcohol intake, and subjective overall stress experience. Their replies demonstrated decreased sleep quantity and efficiency, as well as increased stress, bad mood, and alcohol consumption in the run-up to the election. While similar findings were seen at a lesser level in non-US participants, deteriorating health practises were only shown to be substantially linked with mood and stress among US residents.

The daily surveys, which were given each morning at 8:00 a.m. local time, asked respondents to evaluate the previous night’s sleep by documenting their bedtimes, time necessary to fall asleep, number of awakenings during the night, morning wake time, and time spent napping during the day. They also noted the prior night’s alcohol consumption. Mood was measured using a validated questionnaire as well as questions from a common depression screening instrument.
In terms of sleep, both US and non-US participants reported losing sleep in the run-up to the election; however, US respondents spent much less time in bed in the days before the election. On Election Night, participants in the United States reported waking up often during the night and having worse sleep efficiency.

Participants in the United States who had previously reported consuming alcohol increased their intake on three occasions throughout the evaluation period: Halloween, Election Day, and the day the election was declared by additional media sources, Saturday, November 7. There was no change in alcohol intake among non-US participants over the November evaluation period.
When the researchers examined how these behavioural changes may have influenced the mood and well-being of US individuals, they discovered substantial correlations between sleep and drinking, stress, bad mood, and depression.
The analysis found that stress levels for both U.S. and non-U.S. participants were relatively similar during the assessment period in early October, but there was a substantial increase in reported stress for both groups in the days running up to the November 3 election.

When the election was officially called on November 7, stress levels reduced considerably. This pattern remained true for both US and non-US residents, however changes in stress levels were much higher among US individuals.
Individuals in the United States observed a similar pattern with depression that their counterparts in other countries did not; nonetheless, non-U.S. participants showed substantial declines in negative mood and depression the day after the election was called.
“This is the first study to establish a link between previously observed variations in Election Day public mood and sleep on election night,” Cunningham said. “Moreover, data shows that sleep may impact civic engagement and participation in elections, as well as elections themselves.”

Thus, if the association between sleep and elections is indeed bidirectional, future study will need to understand how public mood and stress impacts on sleep before to an election may affect or even change its outcome.”
The authors caution that the interpretation of their findings is constrained because the bulk of participants’ experience was the accumulation of election stress and subsequent response reliant on their favourite political candidate. More study with a more representative and varied sample is required to confirm the effects of political stress on general public mood and sleep.

Patients with COVID-19 who are placed on ventilators may take a long time to regain consciousness. New study suggests that these delays may have a purpose: they protect the brain from oxygen shortage.

The existence of such a brain-preserving condition may explain why some patients wake up days or even weeks after ceasing respiration, and it implies that physicians should account for these extended recovery intervals when deciding a patient’s prognosis. The researchers link the pattern identified among people who have survived severe COVID-19 with comparable delays known to occur in a tiny percentage of cardiac arrest patients in a report published November 7 in the Proceedings of the National Academy of Sciences.

“The delayed recoveries in COVID-19 individuals are strikingly similar to the few cases we’ve previously identified. We describe a mechanism in this new paper to explain what we’re seeing in both types of patients “Dr. Nicholas D. Schiff, the Jerold B. Katz Professor of Neurology and Neuroscience in the Feil Family Brain and Mind Research Institute and co-director of the Consortium for the Advanced Study of Brain Injury (CASBI) at Weill Cornell Medicine, is a study co-senior author.
He discovered support for this idea, that patients’ brains are defending themselves, in species that can withstand prolonged periods without oxygen, most notably painted turtles.

Dr. Schiff and his colleagues initially identified similar delays in comatose cardiac arrest patients who got cooling treatment to prevent brain damage caused by a lack of blood supply more than a decade ago. In one such example, a 71-year-old patient needed 37 days to awaken before recovering nearly completely.
Dr. Schiff, a neurologist at NewYork-Presbyterian/Weill Cornell Medical Center, performed neurology consultations for COVID-19 patients during the pandemic, and he soon noticed similar, delayed awakenings occurring when patients were taken off ventilators and stopped receiving the sedatives given to them to reduce their movement.

In a previous study of cardiac patients, the researchers discovered a different pattern in brain activity, which was also observed in patients under profound anaesthesia. (Recordings from COVID-19 patients are exceedingly scarce.) Dr. Schiff read that a similar pattern had been observed in the brains of painted turtles, which can survive up to five months without oxygen under ice in the winter. To do so, they engage the same inhibitory circuitry within the brain that is targeted by anaesthetics administered to human cardiac and COVID-19 patients, but in unique methods established through evolutionary adaptations.
Drs. Schiff and Brown hypothesise that the same protective reaction occurs in the patients through coincidence.

“It is our opinion that oxygen deprivation, as well as ICU techniques, including routinely used anaesthetics, expose components of methods that animals utilise to survive in harsh settings,” Dr. Schiff explained.
“These findings may provide fresh insights into the processes by which particular anaesthetics generate unconsciousness, as well as novel techniques for ICU sedation and promoting recovery from consciousness issues,” Dr. Brown stated.
When patients fail to regain consciousness for a lengthy period of time, doctors may propose discontinuing life-sustaining care. For cardiac patients, this criterion is commonly established at 14 days or fewer, however no such recommendations exist for COVID-19.

According to studies, the virus that causes COVID-19, SARS-CoV-2, has a protein that affects cardiac cells. The medicine was discovered to neutralise the protein’s harmful effects on the heart.
Their results, which were based on research conducted by the University of Maryland School of Medicine’s (UMSOM) Center for Precision Disease Modeling with fruit flies and mouse heart cells, were published in Communications Biology, a Nature publication, on September 30, 2022. In comparison to those who have not been infected with the virus, people who have been infected with COVID-19 have a significantly higher risk of developing inflammation of the heart muscle, abnormal heart rhythms, blood clots, stroke, heart attacks, and heart failure for at least a year after infection.

Although scientists created vaccinations and drugs to minimise the severity of COVID-19 illness, these treatments do not protect the heart or other organs from the harm that even a slight infection can cause.
“In order to cure patients in the long run, we must first understand the mechanism behind the sickness.” “Our findings show that individual SARS-CoV-2 proteins can cause significant damage to specific tissues in the body, similar to what has been discovered for other viruses such as HIV and Zika,” said senior author Zhe Han, PhD, Professor of Medicine and Director of the UMSOM Center for Precision Disease Modeling.

“By identifying these damaged mechanisms in each tissue, we can test medications to determine if any of them may reverse the damage; those treatments that show promise can then be explored further in clinical research trials.”
Dr. Han and his colleagues identified the most lethal SARS-CoV-2 proteins in fruit flies and human cells last year. They discovered that the promising medicine selinexor lowered the toxicity of one of these proteins, Nsp6, but not the other.
In their most recent investigation, scientists discovered that Nsp6 is the most lethal SARS-CoV-2 protein in the fly heart.

They discovered that the Nsp6 protein hijacked the fruit fly’s heart cells to activate the glycolysis process, which allows cells to burn the sugar glucose for energy. Normally, heart cells use fatty acids as an energy source, however with heart failure, these cells convert to sugar metabolism in order to heal the damaged tissue. The Nsp6 protein also caused further harm by interfering with the cell’s powerhouse, the mitochondria, which creates energy from sugar metabolism.
The researchers next used the chemical 2-deoxy-D-glucose to inhibit sugar metabolism in fruit flies and mouse cardiac cells (2DG). They discovered that the medication minimised the damage produced by the Nsp6 viral protein to the heart and mitochondria.

“We know that certain viruses hijack the afflicted animal’s cell machinery to modify its metabolism in order to steal the cell’s energy supply, so we assume SARS-CoV-2 does something similar,” Dr. Han said. “Viruses may also use byproducts of sugar metabolism as building blocks to manufacture other viruses.” “So, we expect that this medicine, which restores the heart’s metabolism to pre-infection levels, will be harmful to the virus by cutting off its energy source and destroying the parts it need to replicate.”

The researchers stated that, thankfully, 2DG is affordable and widely utilised in laboratory research. Although the US Food and Medicine Administration has not licenced 2DG for illness treatment, the drug is now being tested in India for the treatment of COVID-19.
“Too many Americans who have recovered from COVID end up with dangerous heart conditions weeks or months later, and we need to learn the fundamental reasons why this is happening,” said Mark T. Gladwin, MD, Vice President for Medical Affairs at the University of Maryland, Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, UMSOM.

“By identifying the Nsp6 protein’s pathways, we can modify the medicines we target for future study, with the ultimate goal of reversing additional cardiac damage in these individuals.”

Patients with COVID-19 who are placed on ventilators may take a long time to regain consciousness. New study suggests that these delays may have a purpose: they protect the brain from oxygen shortage.
The existence of such a brain-preserving condition may explain why some patients wake up days or even weeks after ceasing respiration, and it implies that physicians should account for these extended recovery intervals when deciding a patient’s prognosis. The researchers link the pattern identified among people who have survived severe COVID-19 with comparable delays known to occur in a tiny percentage of cardiac arrest patients in a report published November 7 in the Proceedings of the National Academy of Sciences.

“The delayed recoveries in COVID-19 individuals are strikingly similar to the few cases we’ve previously identified. We describe a mechanism in this new paper to explain what we’re seeing in both types of patients “Dr. Nicholas D. Schiff, the Jerold B. Katz Professor of Neurology and Neuroscience in the Feil Family Brain and Mind Research Institute and co-director of the Consortium for the Advanced Study of Brain Injury (CASBI) at Weill Cornell Medicine, is a study co-senior author.
He discovered support for this idea, that patients’ brains are defending themselves, in species that can withstand prolonged periods without oxygen, most notably painted turtles.

Dr. Schiff and his colleagues initially identified similar delays in comatose cardiac arrest patients who got cooling treatment to prevent brain damage caused by a lack of blood supply more than a decade ago. In one such example, a 71-year-old patient needed 37 days to awaken before recovering nearly completely.
Dr. Schiff, a neurologist at NewYork-Presbyterian/Weill Cornell Medical Center, performed neurology consultations for COVID-19 patients during the pandemic, and he soon noticed similar, delayed awakenings occurring when patients were taken off ventilators and stopped receiving the sedatives given to them to reduce their movement.

Dr. Schiff and his colleagues, including co-author of the current paper, Dr. Emery N. Brown, professor of anaesthesia at Harvard Medical School, Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience in The Picower Institute for Learning and Memory at MIT, and an anesthesiologist at Massachusetts General Hospital, performed a separate analysis of a large cohort of Covid-19 patients from Weill Cornell Medicine and two other major U.S. medical centres. The greater the wait, the more oxygen deprivation they experienced while on the ventilator.

In a previous study of cardiac patients, the researchers discovered a specific pattern in brain activity, which was also observed in patients undergoing profound anaesthesia. (There are very few recordings from COVID-19 patients.) Dr. Schiff discovered a similar pattern in the brains of painted turtles, which can survive up to five months without oxygen under ice in the winter. To do this, they engage the same inhibitory mechanism within the brain that is targeted by anaesthetics administered to human cardiac and COVID-19 patients, but in unique methods created through evolutionary adaptations.
Dr. Schiff and Dr. Brown argue that the same protective reaction occurs in the patients through coincidence.

“It is our opinion that oxygen deprivation, as well as ICU techniques, including routinely used anaesthetics, expose components of methods that animals utilise to survive in harsh settings,” Dr. Schiff explained.
“These findings may provide fresh insights into the processes by which particular anaesthetics generate unconsciousness, as well as novel techniques for ICU sedation and promoting recovery from consciousness issues,” Dr. Brown stated.
When patients fail to regain consciousness for a lengthy period of time, doctors may propose discontinuing life-sustaining care. For cardiac patients, this criterion is commonly established at 14 days or fewer, however no such recommendations exist for COVID-19.

A novel methodology for assessing urine extracellular vesicles (uEVs) in urine samples reveals abnormalities in the kidneys sooner than traditional methods and can also predict renal function deterioration.
A group of researchers from the University of Tokyo examined eurine samples from children with and without chronic kidney disease (CKD). They discovered that when kidney function declines, the size and composition of uEVs vary. This proof of concept might aid in the development of new urine tests that detect the disease early, as well as analogous testing for other disorders. The kidneys are the body’s primary filtration mechanism.

These bean-shaped, fist-sized organs are made up of millions of microscopic filtration units known as nephrons that work tirelessly to keep our blood clean. Unfortunately, chronic kidney disease (CKD) affects 9% of the worldwide population, and the number of cases is increasing.
When nephrons are destroyed, whether by lifestyle, genetic and congenital disorders, or injury, CKD occurs. Many patients may not experience significant symptoms and, as a result, do not seek treatment until the problem has progressed. Because it is difficult to replace injured nephrons entirely, the sooner the diagnosis, the better the prognosis.
Typically, a urine or blood test may inform doctors if a patient has kidney impairment.

These tests, however, can still miss the very early phases of nephron loss that herald the onset of CKD. Researchers at the University of Tokyo sought to see whether there were any additional early indicators of kidney disease, particularly in youngsters.
“We discovered that alterations in microscopic structures called extracellular vesicles in urine are useful in the detection of renal illness,” said Graduate School of Medicine Associate Professor Yutaka Harita. “With reduced renal function, the fraction of bigger vesicles rose. We were also astonished to discover that changes in the chemicals contained in the vesicles may be used to diagnose and predict renal function decrease.”

Extracellular vesicles are particles that are released by nearly all types of cells in our body and perform a variety of tasks. Because urinary extracellular vesicles (uEVs) include proteins from nephrons, they may be exploited as a source of biomarkers (molecules that indicate normal or aberrant processes) for a variety of disorders.
The researchers examined uEVs in urine samples from 26 children with healthy kidneys and 94 children with various kinds of CKD, including those born with smaller-than-average kidneys with fewer nephrons. The causes of CKD in children are less likely to be acquired factors and more likely to be structural abnormalities.

This made it easy for the researchers to identify and understand the alterations in uEVs that are linked to aberrant kidney anatomy.
“We employed nanoscale magnetic microbeads (made of iron oxide particles) coated with a chemical that attaches to EVs to collect extracellular vesicles in urine,” Harita added. “This approach allowed for the effective collection of uEVs even from renal disease patients who could only generate diluted urine. The size and quantity of protein present in the purified extracellular vesicles were measured. We discovered numerous distinct alterations in uEVs from children with CKD. Children with CKD, for example, have reduced amounts of a protein called MUC1 in their uEVs, which is critical for renal function.”

A team of resident physicians delivered a letter to top Union Health Ministry officials requesting the deployment of the Central Industrial Security Force (CISF) or the Central Reserve Police Force (CRPF) at hospitals so that they can operate freely in a secure and healthy atmosphere. “We would like to make a humble appeal on behalf of all the physicians in our nation to kindly deploy CISF/CRPF at their hospital so they may operate freely in a secure and healthy environment,” stated the letter submitted by the Ram Manohar Lohia Hospital Resident Doctors Association.

“The physicians worked diligently away from home and family during COVID and continue to do so now. All they seek is that the government protect them not from the patients, but from the nefarious forces of society “According to the letter.
The deputy director of Dr VK Sharma Lady Hardinge Medical College and SMT SK Hospital has issued a letter stating, “withdrawal of services of Marshal/Bouncer at LMC and associated hospital with immediate effect.”
Following directions from Union Health Minister Dr Mansukh Mandaviya, the services of marshals and bouncers were terminated with immediate effect from Lady Hardinge Medical College and related institutions.

In persons with inflammatory bowel disease, the intestine becomes inflamed, which can thicken the gut wall and result in a potentially deadly obstruction of the intestinal tube. This mystery condition known as “fibrosis” affects 20 to 50% of Crohn’s disease and ulcerative colitis patients throughout the course of their lives. “Aside from surgery to remove the blocked section of intestine, there are currently no approved treatments for this condition,” said Dr. Simon Hirota, PhD, Canada

Research Chair in Host-Microbe Interactions and Chronic Disease and member of the Snyder Institute for Chronic Diseases at the University of Calgary’s Cumming School of Medicine. Hirota’s recent study, which was published in the journal Cellular and Molecular Gastroenterology and Hepatology, sets the door for the development of a potentially viable fibrosis therapy. The study included researchers from the Albert Einstein College of Medicine in New York and the University of Calgary.

The researchers looked at the bacteria that dwell in the human gut, dubbed “the inner tube of life,” and create microbial metabolites, which are metabolic byproducts that prevent inflammation and gut wall thickening. These compounds, as well as the body’s natural receptors for detecting them, are less common in those suffering from inflammatory bowel disease.
Hirota observed that, while the gut must mend itself after an injury, the “over-exuberant” continuous healing seen in inflammatory bowel diseases causes changes to the gut wall that feed disease.
“We’re now suspecting that the fibroblast cells just under the lining may also play a role in perceiving and reacting to metabolites,” Hirota added.

The study focused on PXR, a chemical sensor or receptor in the gut that is important in aiding gut repair. They focused on the interaction between this receptor and a metabolite known as IPA.
The researchers employed cells from mice with the PXR receptor removed to identify the cells involved in the interaction between the host and the chemicals produced by gut bacteria. They employed human intestinal cells to confirm their findings in the animal model.
Medication designed to directly target these sensors, according to the study, may offer a novel strategy to treating inflammation-related intestinal blockage.

Co-author Dr Sridhar Mani, MD, and his research team produced synthetic compounds based on the structure of the IPA metabolite in the same way as natural IPA reduces inflammation.
“This novel research has resulted in a field-leading article that clearly implicates PXR as a crucial target for fibrosis,” adds Mani, an Albert Einstein College of Medicine professor. “We now seek to leverage microbial metabolite mimicry as a way to target PXR in order to avert this terrible IBD consequence.” Clinical studies would be the next stage in determining if synthetic compounds have a good effect on fibrosis and human gut remodelling. The “synthetic metabolite,” according to Hirota, should ideally be in a form that can be digested, passed through the stomach, and then released in the injured portions of the gut.

A new medication called Baxdrostat has been shown to significantly lower high blood pressure (hypertension) in patients who may not respond to current treatments for the condition, according to findings from a phase II trial conducted by a researcher from Queen Mary University of London and associates at CinCor Pharma, USA.
The trial findings reflect the first time that a long-needed new class of drugs to treat resistant hypertension has been successfully developed and tested. They were presented at the American Heart Association Scientific Sessions conference and published in the New England Journal of Medicine.

During the 12-week study, 248 individuals were given either a placebo or a once-daily dose of Baxdrostat at various doses. Despite taking three or more blood pressure drugs at the time of trial entry, none of these patients’ blood pressure was under control. Baxdrostat was given to the patient in addition to his or her normal meds in dosages ranging from 2 mg to 1 mg to 0.5 mg.
At the end of the 12-week period, the group that received the most Baxdrostat saw a 20-point drop in blood pressure. An 11-point difference between this group and the placebo-treated group was a seldom reported differential in any single blood pressure-lowering medicine.

Baxdrostat works by preventing the body from manufacturing aldosterone, a hormone that regulates the body’s salt levels. Baxdrostat lowered aldosterone levels in the blood and urine. According to the study, this form of hypertension is caused in part by an excess of the hormone aldosterone and leads in a considerable reduction in blood pressure in individuals with resistant hypertension to standard therapy.
The difficulty in developing such a drug has been connecting the enzyme that makes aldosterone to another enzyme that also creates cortisol, a critical steroid hormone.

“The results of this first-of-its-kind drug are exciting, although more testing is required before we can draw comparisons with any existing medications,” said Professor Morris Brown, co-senior author of the study and Professor of Endocrine Hypertension at Queen Mary University of London.
“The success of earlier medications in individual individuals can vary significantly, but a feature of this new class is that it can be anticipated to operate well in people whose aldosterone hormone has made them resistant to prior therapies.”

High blood pressure is the leading cause of strokes, heart attacks, and renal failure. Because the aetiology is unknown, the majority of persons who have the disorder require lifelong pharmaceutical therapy.
High blood pressure affects one-third of individuals in the UK, making it one of the most common illnesses among adults. In recent years, it has been discovered that a gene mutation in the adrenal glands causes the overproduction of the steroid hormone aldosterone in 5-10% of persons who have it. This might affect over 500,000 individuals in the United Kingdom.
Aldosterone causes the body to retain salt, raising blood pressure.

Patients with high aldosterone levels in their blood are resistant to the most commonly administered hypertension medicines.
Professor Brown has worked directly on the medicine for almost 10 years, providing assistance on both the Baxdrostat study in the United States and the product’s previous development. He worked closely with both the pharmaceutical corporations that developed the drug and the start-ups that secured the licence.